About
Compound Digest is an independent clinical intelligence platform tracking the GLP-1 and peptide therapeutics space. We monitor clinical readouts, regulatory decisions, manufacturing and supply dynamics, and deal flow across the incretin and peptide landscape.
Our coverage spans the full pipeline — from preclinical candidates to approved therapies — with a focus on what each development means for the standard of care. Every entry in the Compound Index links to a data sheet covering target, mechanism, indication, developer, and clinical status.
We do not accept advertising from the companies we cover. Editorial decisions are made independently of commercial relationships, and all factual claims are sourced to primary literature, trial registries, or official regulatory communications.
Methodology
Compound status reflects the most advanced publicly disclosed clinical stage as reported in trial registries and company communications. Molecular data is sourced from peer-reviewed publications and regulatory labels. News items are dated to the date of public disclosure.